Polarean Imaging Plc operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The company is headquartered in Durham, North Carolina and currently employs 26 full-time employees. The company went IPO on 2018-03-29. The firm and its subsidiary company, Polarean, Inc., operate as investigational drug-device combination companies operating in the high-resolution medical imaging research space. The firm has developed the hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW (xenon Xe 129 hyperpolarized). The company develops equipment that enables existing MRI systems to achieve an improved level of pulmonary functional imaging. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream. Its technology provides an investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform.
Follow-Up Questions
Quel est le ratio P/E de Polarean Imaging PLC (PLLWF) ?
Le ratio P/E de Polarean Imaging PLC est de N/A
Qui est le CEO de Polarean Imaging PLC ?
Dr. Christopher Von Jako est le Chief Executive Officer de Polarean Imaging PLC, il a rejoint l'entreprise depuis 2023.
Quelle est la performance du prix de l'action PLLWF ?
Le prix actuel de PLLWF est de 0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Polarean Imaging PLC ?
Polarean Imaging PLC appartient à l'industrie Health Care et le secteur est Health Care
Quelle est la capitalisation boursière de Polarean Imaging PLC ?
La capitalisation boursière actuelle de Polarean Imaging PLC est de $0
Est-ce que Polarean Imaging PLC est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Polarean Imaging PLC, y compris 1 achat fort, 3 achat, 1 maintien, 0 vente et 1 vente forte
